このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cyclo Therapeutics マネジメント

マネジメント基準チェック /44

Cyclo Therapeutics'の CEO はN. Fineで、 Sep2015年に任命され、の在任期間は 8.75年です。の年間総報酬は$ 672.89Kで、 80.4%給与と19.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.6%を直接所有しており、その価値は$ 922.32K 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と9.6年です。

主要情報

N. Fine

最高経営責任者

US$672.9k

報酬総額

CEO給与比率	80.4%
CEO在任期間	8.8yrs
CEOの所有権	2.6%
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	9.6yrs

経営陣の近況

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

Jan 05

How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Dec 12

CEO報酬分析

Cyclo Therapeutics の収益と比較して、N. Fine の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$673k	US$541k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$541k	-US$15m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$508k	-US$14m
Sep 30 2021	n/a	n/a	-US$14m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$489k	US$400k	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$490k	US$400k	-US$8m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	US$467k	US$400k	-US$4m
Sep 30 2018	n/a	n/a	-US$4m
Jun 30 2018	n/a	n/a	-US$4m
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$441k	US$400k	-US$4m

報酬と市場: N.の総報酬 ($USD 672.89K ) は、 US市場 ($USD 678.50K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: N.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

N. Fine (67 yo)

8.8yrs

在職期間

US$672,888

報酬

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
N. Fine	CEO & Director	8.8yrs	US$672.89k	2.6% $ 966.9k
C. Strattan	Founder & Director	no data	US$33.00k	1.03% $ 384.8k
Joshua Fine	CFO & Secretary	10.4yrs	US$463.98k	0.059% $ 22.0k
Michael Lisjak	Senior VP of Business Development & Chief Regulatory Officer	4.9yrs	US$473.21k	0.043% $ 16.1k
Jeffrey Tate	COO, Chief Quality Officer & Director	8.8yrs	US$255.14k	0.32% $ 119.7k
Lori McKenna	Global Head of Patient Advocacy	3.1yrs	データなし	データなし
Karen Mullen	Interim Chief Medical Officer	1.4yrs	データなし	データなし

6.8yrs

平均在職期間

66yo

平均年齢

経験豊富な経営陣: CYTHの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
N. Fine	CEO & Director	10.3yrs	US$672.89k	2.6% $ 966.9k
C. Strattan	Founder & Director	34.4yrs	US$33.00k	1.03% $ 384.8k
Jeffrey Tate	COO, Chief Quality Officer & Director	13.8yrs	US$255.14k	0.32% $ 119.7k
William Shanahan	Independent Director	8yrs	US$40.13k	0.44% $ 163.5k
Markus Sieger	Independent Chairman	10.3yrs	US$66.38k	1.15% $ 427.4k
Rita Colwell	Co-Chair of Scientific Advisory Board	no data	データなし	データなし
Sharon Hrynkow	Co-Chairman of Scientific Advisory Board	9.6yrs	US$600.09k	データなし
F. Ostronic	Independent Vice Chairman	10.2yrs	US$41.25k	1.22% $ 453.4k
Caroline Hastings	Member of Scientific Advisory Board	9.3yrs	データなし	データなし
Benny Liu	Member of Scientific Advisory Board	9.1yrs	データなし	データなし
Gerald F. Cox	Member of Scientific Advisory Board	2.8yrs	データなし	データなし
Randall Toig	Independent Director	6.3yrs	US$35.63k	0.40% $ 149.8k

9.6yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: CYTHの取締役会は経験豊富であると考えられます ( 9.6年の平均在任期間)。

Cyclo Therapeutics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

CEO & Director exercised options to buy US$293k worth of stock.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Recent updates

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Cyclo Therapeutics, Inc. Appoints Russ Belden as Acting Chief Commercial Officer

Cyclo Therapeutics, Inc. Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on Agreement of Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics, Inc. Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer

Cyclo Therapeutics, Inc. Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

New 90-day high: US$13.15

Independent Chairman recently bought US$64k worth of stock

Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

マネジメント基準チェック /44